Seattle Genetics Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/20/2023)
| Balance Sheet | Total Assets | 3,674,530,000.00 | ROE | – |
| Balance Sheet | Total Equity | 2,803,820,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -77,340,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -531,091,000.00 | – | – |
| Cashflow | Operating Cash Flow | -453,751,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -3.30 | Div. Yield | – |
| Income | Net Income | -610,308,000.00 | P/E | – |
| Income | Shares Outstanding | 184,676,000.00 | P/B | – |
| Income | Total Revenue | 1,962,410,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Seattle Genetics, Inc. is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (s ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.seattlegenetics.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more